Atopic dermatitis (AD) is a heterogeneous inflammatory skin disease arising from genetic and environmental factors that disrupt skin barrier function and immune response. 1 Current management involves treatment combinations to suppress inflammation, restore skin barrier function, and prevent superinfection. 2 Systemic immunosuppressants are reserved typically for treatment of moderate-to-severe AD but are associated with adverse events (AEs) and not suitable for longterm use. 2 Therefore more effective and well-tolerated therapies are required that target the etiologic mechanisms of AD pathophysiology rather than simply providing symptom relief.
A key feature of AD is upregulation of IL-13 and IL-4 in lesional [3] [4] [5] and nonlesional 6, 7 skin, suggesting both cytokines can contribute to AD pathogenesis. [3] [4] [5] [6] [7] Moreover, AD severity is associated with increased IL-13 and associated chemokine mRNA and serum levels, whereas reductions in IL-13 concentrations have correlated with treatment response and improved clinical outcomes. 6, 7 Although treatment with dupilumab, a human mAb that inhibits both IL-4 and IL-13 signaling, has demonstrated improvements in AD symptoms, [8] [9] [10] the relative contribution of each of these cytokines to AD pathogenesis is unclear.
Tralokinumab is a fully human IgG 4 mAb that potently and specifically binds to and neutralizes the effects of IL-13. This phase IIb study (NCT02347176) investigates the efficacy, safety, and tolerability of tralokinumab in adults with moderate-to-severe AD. In exploratory analyses, serum biomarker assays were used to identify participants with increased dipeptidyl peptidase-4 (DPP-4) and periostin concentrations and to determine whether they experienced greater treatment responses.
METHODS

Study design
This phase IIb randomized, double-blind, placebo-controlled, dose-ranging study in participants with moderate-to-severe AD took place across 55 sites in Australia, Canada, Germany, Japan, Poland, and the United States. Eligible participants were aged 18 to 75 years, with a physician-confirmed diagnosis of AD (according to Hanifin and Rajka 12 ), AD body surface area involvement of 10% or more, Eczema Area Severity Index (EASI) score of 12 or more, SCORAD score of 25 or more, and Investigator's Global Assessment (IGA) score of 3 or more (6-point scale: 0, clear; 1, almost clear; 2, mild; 3, moderate; 4, severe; and 5, very severe). During the 2-week run-in period and treatment period, participants were treated at least once daily with concomitant class 3 13 topical glucocorticoids to reflect the expected clinical use of biologics for moderate-to-severe AD. A run-in period of 2 weeks was considered adequate in length to identify and exclude any participants with a treatment response to topical glucocorticoids and to eliminate any potential issues associated with a variable response to study treatment. Participants were randomized 1:1:1:1 to receive placebo or tralokinumab (45, 150, or 300 mg) subcutaneously every 2 weeks for 12 weeks before a 10-week follow-up period. Detailed inclusion and exclusion criteria are provided in the Methods section in this article's Online Repository at www.jacionline.org.
The protocol and amendments (see Table E1 in this article's Online Repository at www.jacionline.org) were approved by the independent ethics committee or institutional review board at each study center. Informed written consent was obtained from all participants. The study was conducted according to the ethical principles of the Declaration of Helsinki.
Study end points
Coprimary efficacy end points were change in EASI score from baseline to week 12 and percentage of participants achieving an IGA response of 0 (clear) or 1 (almost clear) with a reduction of 2 grades or more from baseline to week 12. Secondary end points included change from baseline in EASI and SCORAD scores by visit up to week 22, percentage of participants with a reduction of 50% or more in EASI score and reduction of 50% or more in SCORAD score at week 12, and percentage of participants achieving an IGA response by visit up to week 22. Change in pruritus numeric rating scale and Dermatology Life Quality Index from baseline to week 12 were also measured. Safety end points measured through week 22 included treatment-emergent adverse events (TEAEs) and treatment-emergent serious adverse events (TESAEs). The immunogenicity potential of tralokinumab (measured by percentage of participants with an anti-drug antibody [ADA] response) was determined. Samples for ADA response were taken at day 1 and weeks 4, 12, and 22.
Exploratory analyses
The percentage of participants achieving a reduction of 75% or more in EASI score by visit up to week 22 was measured. Primary end points were also evaluated in subgroups defined by serum periostin and DPP-4 (biomarkers for IL-13 activity), CCL17/thymus-and activation-regulated chemokine (TARC), and IgE concentrations equal to or greater than or less than the total population median baseline concentration. Adjusted mean change from baseline in serum DPP-4 concentration and adjusted mean ratio to baseline for serum periostin, CCL17/TARC, and IgE were reported over time.
Statistical methods
The study was powered at 80% to detect the minimal clinically important 14 7-point difference in EASI score change from baseline between tralokinumab and placebo, assuming an SD of 10 points. Furthermore, combining data from the 2 highest tralokinumab dose groups would provide 80% power to detect a difference in IGA response compared with placebo of 35% versus 10%. A hierarchical testing strategy was used to preserve type I error rates for the coprimary efficacy end points (see the Methods section in this article's Online Repository).
The primary population for analysis was the intention-to-treat (ITT) population, which was defined as all participants treated with study drug. Safety data were reported according to the highest dose received by each participant measured in the as-treated population.
Baseline demographics and safety data were summarized descriptively. Continuous end points were analyzed by using a mixed-model repeated-measures analysis. The model included factors of treatment, visit, and treatment-by-visit interaction and was adjusted for baseline as a covariate. The adjusted mean changes between tralokinumab and placebo, 95% CIs, and 2-sided P values were calculated. Binary end points were analyzed at each visit by logistic regression with treatment as a categorical factor and baseline as a covariate. Covariate-adjusted differences in percentages with 95% CIs were calculated for binary end points. 15 Results from visits after a participant had received prohibited medications were excluded from the analysis. For continuous end points, no imputation for missing data was applied. For binary end points, a last observation carried forward approach was used. Exploratory analyses of biomarker data used similar statistical methods, as described for the primary analysis.
RESULTS
The first participant was enrolled on January 23, 2015, and the first participant was dosed on February 13, 2015. Of the 299 participants who were screened, 204 were randomized (placebo, n 5 51; 45 mg of tralokinumab, n 5 50; 150 mg of tralokinumab, n 5 51; and 300 mg of tralokinumab, n 5 52) and included in the ITT and as-treated populations (see Fig E1 in this article's Online Repository at www.jacionline.org). Baseline demographics and disease characteristics were similar between treatment groups (see Table E2 in this article's Online Repository at www.jacionline.org).
Efficacy outcomes
At week 12, the adjusted mean difference from baseline in EASI score was significantly different than the value in the placebo group: 24.36 (95% CI, 28.22 to 20.51; P 5 .03) for the 150-mg tralokinumab group and 24.94 (95% CI, 28.76 to 21.13; P 5 .01) for the 300-mg tralokinumab group (Table I) . Testing the 150-and 300-mg tralokinumab pooled doses compared with placebo did not demonstrate a significant difference in the percentage of participants with an IGA response at week 12 (23.0% vs 11.8%, P 5 .10); therefore the hierarchical testing procedure was discontinued. However, numeric improvements in IGA response rates were observed with increasing doses of tralokinumab (Fig 1, D) . The greatest absolute percentage difference from placebo was observed in participants treated with 300 mg of tralokinumab (26.7% vs 11.8% [114.8%]; 95% CI, 0.0 to 29.7; P 5 .06; Table I ).
Improvements in adjusted mean change from baseline in EASI score were evident at week 4 and maintained beyond week 12 for participants treated with 300 mg of tralokinumab (Fig 1, A) . A greater adjusted percentage of tralokinumab-treated participants achieved a reduction of 50% or more in EASI score versus placebo at week 12, and differences were most substantial in the 300-mg tralokinumab group (73.4% vs 51.9%, P 5 .03; Fig 2, A) . A similar trend was observed when analyzing the percentage of participants with a reduction of 75% or more in EASI score (42.5% in the 300-mg tralokinumab group vs 15.5% in the placebo group, P 5 .003; Fig 2, A) .
Improvements in SCORAD score versus placebo were achieved for participants treated with 150 and 300 mg of tralokinumab (adjusted mean difference, 29.42 [95% CI, 215.56 to 23.29; P 5 .003] and 29.84 [95% CI, 215.91 to 23.77; P 5 .002], respectively). Improvements in SCORAD score were observed from week 2 onward for all doses of tralokinumab and maintained beyond week 12, with the greatest effect observed in participants treated with 300 mg of tralokinumab (Fig 3, A) . The percentage of participants with a reduction of 50% or more in SCORAD score at week 12 was greater in the 150-mg tralokinumab group (44.2%, P 5 .008) and the 300-mg tralokinumab group (44.1%, P 5 .009) versus placebo (19.5%; Fig 2, B) .
Patient-reported outcomes
Participants demonstrated improvements from baseline at week 12 in pruritus numeric rating scale (7-day mean) scores versus those receiving placebo when receiving 45 or 300 mg of tralokinumab (adjusted mean difference, 20.77 [95% CI, 21.52 to 20.02; P 5 .04] and 21.14 [95% CI, 21.88 to 20.41; P 5 .002], respectively). These improvements were observed from week 1 onward for all tralokinumab doses and maintained beyond week 12 (Fig 3, B) . Furthermore, improvements in Dermatology Life Quality Index score were reported at week 12 for those receiving 300 mg of tralokinumab versus placebo (adjusted mean difference, 23.51 [95% CI, 26.00 to 21.02; P 5 .006]). However, these improvements were not maintained beyond the 12-week treatment period (Fig 3, C) .
Biomarker subgroup analysis
Median baseline serum DPP-4, periostin, CCL17/TARC, and IgE concentrations were 265.8 ng/mL, 29.8 ng/mL, 1478.2 ng/mL, and 3045.6 kU/L, respectively. Exploratory analyses of adjusted mean change from baseline over time for EASI scores and adjusted percentage of participants with an IGA response are shown in Fig 1 for the DPP-4-high (Fig 1, B and C) and periostin-high (Fig 1, E and F Table I) .
No clinically meaningful differential effects on treatment response were observed for the CCL17/TARC and IgE subgroups (see Table E3 (Fig 1, A*) , DPP-4-high subgroup (Fig 1, B ) , and periostin-high subgroup (Fig 1, C à) . D-F, Adjusted percentage of participants with an IGA response at week 12 for the ITT population (Fig 1, D*) , DPP-4-high subgroup (Fig 1, E ) , and periostin-high subgroup (Fig 1, Fà) . 
Immunogenicity profile
Tralokinumab demonstrated low potential to cause immunogenicity; only 1 participant (treated with 300 mg of tralokinumab) had positive test results for a low-titer ADA response after dosing, indicating a transient response. The participant was not symptomatic.
Safety assessments
All participants included in the safety analysis received at least 1 dose of study drug. Most TEAEs were considered mild or moderate. Those considered study drug related were experienced by 17.6% of participants, with the most frequent being upper respiratory tract infection and headache (Table II) . Injection-site reactions were reported by 3.9% of participants in the placebo group and 5.2% in the pooled tralokinumab group (see Table  E4 in this article's Online Repository at www.jacionline.org). Conjunctivitis was experienced by 3.9% of participants in the placebo group, 2.0% of participants in the 45-mg tralokinumab group, and 5.9% of participants in the 150-mg tralokinumab group (see Table E5 in this article's Online Repository at www.jacionline.org). Other incidences of viral infection were also low (see Table E5 ); 3 incidents of nasopharyngitis (1 each in the placebo, 45-mg tralokinumab, and 300-mg tralokinumab groups) and 1 incident of oral herpes (45-mg tralokinumab group) were considered study drug related.
Few TESAEs were reported, and all were considered unrelated to study drug (Table II) . Ten participants discontinued treatment because of TEAEs, with the highest frequency in the placebo group (Table II and see Table E6 in this article's Online Repository at www.jacionline.org).
DISCUSSION
Our study provides evidence for targeting IL-13 in patients with AD. Treatment with 150 or 300 mg of tralokinumab subcutaneously every 2 weeks for 12 weeks achieved clinically significant improvements in EASI scores from week 4 in participants with moderate-to-severe AD who received concomitant topical glucocorticoids. IL-13 upregulates DPP-4 and periostin expression, and both are considered biomarkers of IL-13 signaling. [16] [17] [18] [19] In exploratory analyses additional treatment benefits were observed in DPP-4-and periostin-high subgroups, driven in part by a smaller reduction in EASI scores in the placebo group for DPP-4-high participants than in the ITT population. Previous AD studies have largely focused on reversing clinical symptoms, with few documenting biomarker changes. 6, 7, [20] [21] [22] [23] [24] In our study we observed greater changes in serum biomarker concentrations versus placebo after tralokinumab treatment. Biomarkers are playing an increasingly important role in predicting treatment response, and our results are likely to assist in progressing AD treatment toward a more personalized approach.
Participants entering the study had not achieved an adequate response to stable topical glucocorticoids during the 2-week run-in period and therefore represent a population with moderate-to-severe AD and major unmet treatment needs. The clinically meaningful benefits observed by combining tralokinumab treatment with topical glucocorticoids suggest that tralokinumab could demonstrate improvements in participants whose symptoms cannot be effectively controlled by topical glucocorticoids alone. These agents are widely used in AD treatment; however, they are associated with multiple systemic and topical side effects, precluding long-term use on a large body surface area. 25 Therefore agents that reduce the need for high-dose topical glucocorticoids are greatly needed.
The positive results of our study add to the growing body of evidence supporting a central role for T H 2 inflammation in AD pathogenesis. 4, 20, 26, 27 These include studies of dupilumab, an inhibitor of both IL-13 and IL-4 signaling, which have shown improved clinical responses in adults with moderate-to-severe AD in a dose-dependent manner [8] [9] [10] 20, 28 and data from a phase IIb study showing benefits with lebrikizumab, which inhibits IL-13 signaling. 29 In our study participants received treatment with topical glucocorticoids during the 2-week run-in period before randomization. Participants who demonstrated improvements in AD symptoms on this treatment regimen such that they no longer met the study's inclusion criteria (EASI score > _12, SCORAD score > _25, or IGA score > _3) were then excluded. Therefore, given the differences in study design, outcomes assessed, and participant selection criteria, it is difficult to compare the efficacy of tralokinumab with other agents targeting IL-13 in AD treatment. Future phase III studies of tralokinumab both as monotherapy and in conjunction with topical glucocorticoids are needed to provide further understanding of the relevant contribution of IL-13 alone to AD compared with IL-4 and IL-13 in combination. It might also be of benefit for future studies to analyze clinical response in participants classified by AD form (classical, nummular, or prurigo) to determine whether response is dependent on these factors. The safety profile of tralokinumab in patients with AD was similar to results from previous trials of tralokinumab in patients with asthma. The most common events were upper respiratory tract infections and headache, the majority of TEAEs were mild or moderate, and none of the 5 TESAEs reported across the tralokinumab groups were considered study drug related. 30, 31 These findings are broadly in line with those reported in studies of dupilumab [8] [9] [10] 32, 33 and lebrikizumab 29, 34 in patients with AD and asthma. Conjunctivitis has been reported at a higher rate in participants receiving dupilumab relative to placebo. 8, 10 Although not predefined as an AE of special interest in our study, conjunctivitis was reported infrequently, with no incidents considered study drug related.
Only 1 participant had a positive test result for an ADA response to tralokinumab, and they were asymptomatic. This is comparable with immunogenicity results from asthma trials, which reported no 31, [35] [36] [37] or few participants (2/151 participants receiving 300 mg of tralokinumab every 4 weeks) 30 with positive test results for an ADA response.
The observed improvements in placebo-treated participants indicate that topical glucocorticoids provided partial benefit, despite all participants having inadequate disease control with such therapy at enrollment. Although a study of tralokinumab monotherapy would provide a more definitive measurement of efficacy than in combination with topical glucocorticoids, in clinical practice it is expected that biologics will be prescribed concomitantly to topical therapies. Therefore our study reflects a real-world setting, demonstrating tralokinumab efficacy with concomitant topical glucocorticoids and providing further support for the role of IL-13 in AD pathogenesis.
In conclusion, tralokinumab has an acceptable safety and tolerability profile and appears to provide early and sustained improvements in disease symptoms in participants with moderate-to-severe AD. In the ITT population clinical efficacy was greatest in participants treated with 300 mg of tralokinumab; participants with increased IL-13 activity demonstrated further improvements in treatment response relative to the ITT population, supporting a key role for IL-13 in the pathologic mechanisms of AD. Phase III studies are required to confirm these findings.
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Clinical implications: Tralokinumab and concomitant topical glucocorticoids demonstrated meaningful improvements across clinical and patient-reported outcomes. Greater treatment responses experienced by participants with increased IL-13 activity support a key role of IL-13 in AD pathophysiology. 
